You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)核數師要求調查2.27億元投資事項
阿思達克 03-18 09:19
基石藥業-B(02616.HK)公布,其抗PD-1抗體nofazinlimab (CS1003)聯合侖伐替尼一線治療晚期肝細胞癌(HCC)患者的國際多中心III期註冊研究CS1003-305成功達成預設患者入組目標。此外,公司普拉替尼用於治療轉染重排(RET)融合陽性的局部晚期或轉移性非小細胞肺癌(NSCLC)的新藥上市申請已在香港獲受理。 另外,公司於截至去年12月底止年度的審核過程中,發現用約為2.27億元的資金於去年7月透過認購CMB International Global Products Limited發行的基金掛鉤票據用於投資一家於開曼群島註冊的獨立投資組合公司。公司正與核數師協力提供其他有關投資事項的包括有效性及可收回性相關的資料。 根據核數師的要求,審核委員會正安排委聘專家對投資事項進行獨立調查,調查結果將第一時間向董事會審核委員會匯報。董事會擬根據調查結果,將可能妥善評估截至2021年12月31日投資事項的公平值。而公司目前仍在敲定集團截至去年12月底止年度的年度業績。 至於公司近期股價及成交量出現不尋常波動,公司確認集團營運保持正常,並會繼續照常開展其業務。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account